Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) Non Operating Income: 2015-2025

Historic Non Operating Income for Seres Therapeutics (MCRB) over the last 11 years, with Sep 2025 value amounting to $30.7 million.

  • Seres Therapeutics' Non Operating Income rose 236.26% to $30.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $102.7 million, marking a year-over-year increase of 741.89%. This contributed to the annual value of -$14.1 million for FY2024, which is 384.01% down from last year.
  • According to the latest figures from Q3 2025, Seres Therapeutics' Non Operating Income is $30.7 million, which was up 510.45% from $5.0 million recorded in Q2 2025.
  • Seres Therapeutics' Non Operating Income's 5-year high stood at $59.9 million during Q1 2025, with a 5-year trough of -$22.5 million in Q3 2024.
  • Over the past 3 years, Seres Therapeutics' median Non Operating Income value was $2.7 million (recorded in 2024), while the average stood at $7.9 million.
  • Its Non Operating Income has fluctuated over the past 5 years, first plummeted by 730.55% in 2024, then surged by 3,803.45% in 2025.
  • Over the past 5 years, Seres Therapeutics' Non Operating Income (Quarterly) stood at -$356,000 in 2021, then crashed by 37.36% to -$489,000 in 2022, then surged by 571.78% to $2.3 million in 2023, then spiked by 206.76% to $7.1 million in 2024, then spiked by 236.26% to $30.7 million in 2025.
  • Its last three reported values are $30.7 million in Q3 2025, $5.0 million for Q2 2025, and $59.9 million during Q1 2025.